Alebund Pharma expects H1 revenue RMB 103 million-RMB 106 million, up about 750%-775%

PUBT · 1d ago
Alebund Pharma expects H1 revenue RMB 103 million-RMB 106 million, up about 750%-775%
  • Alebund flagged revenue of RMB 103 million–RMB 106 million for the six months ended June 30, 2026, up about 750%–775%.
  • Loss for the period seen at RMB 158 million–RMB 178 million, narrowing about 15%–25% from RMB 209.7 million a year earlier.
  • Outlook reflects licensing revenue tied to AP306 agreements with R1 Therapeutics, supported by higher Mircera sales.
  • Loss also narrowed due to a one-off end to a pre-listing share redemption obligation, eliminating related interest accruals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260806-12274974), on August 06, 2026, and is solely responsible for the information contained therein.